Sacco, one of the leading and most historically relevant biotech companies in both research and the production of lactic bacteria and probiotics for the food, nutraceutical and pharmaceutical industries, has recently acquired the majority of Synbiotec, a spin-off company of the University of Camerino specialized in the research and development of probiotics for applications in human and animal nutrition.
The potential synergies between these two companies are numerous: both share the strategic goal of contributing to the improvement of both humans’ and animals’ welfare through the study, research and development of natural ingredients and processes; and both commit to supplying probiotic bacterial strains with the highest levels of quality and innovation always keeping in tune with the demands of a constantly evolving market.
"We are deeply convinced that the synergies existing between the two companies, which have over time had the chance to get to know each other, and which are further reinforced through this acquisition, will lead to the landmark establishment of a pole of excellence in the Italian industry of probiotics for human and animal health. This will also undoubtedly favour research, development and innovation in the production and improvement of products for the well-being of consumers. Another shared fundamental pillar for both companies, which paves the ground for virtuous cooperation, is the cardinal importance both assign to human capital for the achievement of their core goals.” says Martino Verga, CEO of Sacco Srl.
“We are thrilled to be able to share our probiotic research experience with a large international group like Sacco. The strength of its history and its global presence will allow us to explore together new applications for the probiotic market with the shared intention of improving the health and well-being of consumers. The participation of the Sacco group in Synbiotec is a great opportunity for our company, and I am sure it will help us grow and further establish ourselves in the market”, says Maria Cristina Verdenelli, President and Founding Partner of Synbiotec.